• Publications
  • Influence
Revision of the American Joint Committee on Cancer staging system for breast cancer.
This revised staging system for breast carcinoma will be officially adopted for use in tumor registries in January 2003 and will be useful for the uniform accrual of outcome information in national databases.
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
A 30-probe set pharmacogenomic predictor predicted pCR to T/FAC chemotherapy with high sensitivity and negative predictive value.
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
Neoadjuvant chemotherapy has the capacity to completely clear the breast and axillary lymph nodes of invasive tumor before surgery and patients with LABC who have a pCR in the breastand axillary nodes have a significantly improved disease-free survival rate.
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth
Adding trastuzumab to chemotherapy, as used in this trial, significantly increased pathologic complete response (pCR) rate without clinical congestive heart failure, according to the small sample size.
The cognitive sequelae of standard‐dose adjuvant chemotherapy in women with breast carcinoma
A prospective, longitudinal trial that incorporates baseline neuropsychologic evaluations is necessary to determine to what extent cognitive dysfunction is attributable to chemotherapy in this population of patients with breast carcinoma.
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
ABI-007 offers several features of clinical interest, including rapid infusion rate, absence of requirement for premedication, and a high paclitaxel MTD, which provides support for Phase II trials to determine the antitumor activity of this drug.
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.
Patients with HER2-positive T1abN0M0 tumors have a significant risk of relapse and should be considered for systemic, anti-HER2, adjuvant therapy.
‘Chemobrain’ in breast carcinoma?
Chemotherapy‐induced cognitive dysfunction in patients with breast carcinoma has been described previously. However, those studies only assessed patients' postchemotherapy cognitive functioning and
Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation.
Patients with tumors >/= 4 cm or at least four involved nodes experience LRR rates in excess of 20% and should be offered adjuvant irradiation and may benefit from postmastectomy irradiation.
Breast cancer. Clinical practice guidelines in oncology.